Co-Authors
This is a "connection" page, showing publications co-authored by Ravi Salgia and Ramasamy Jagadeeswaran.
Connection Strength
1.427
-
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42.
Score: 0.298
-
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
Score: 0.281
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.259
-
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
Score: 0.081
-
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008 Dec; 47(12):1025-37.
Score: 0.079
-
FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7.
Score: 0.079
-
C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther. 2008 Jun; 7(6):856-63.
Score: 0.075
-
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
Score: 0.072
-
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
Score: 0.071
-
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53.
Score: 0.071
-
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 2005 Feb 15; 65(4):1479-88.
Score: 0.061